Chapter 1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Market Segmentation
1.3. Research Scope
1.4. Research Methodology
1.4.1. Phase I-Secondary Research
1.4.2. Phase II-Primary Research
1.4.3. Phase III-Expert Panel Review
1.4.4. Assumptions
Chapter 2. Executive Summary
2.1. Global Biologics Market Portraiture
2.2. Global Biologics Market, by Product, 2017 (US$ Bn)
2.3. Global Biologics Market, by Disease, 2017 (US$ Bn)
2.4. Global Biologics Market, by Geography, 2017 (US$ Bn)
Chapter 3. Global Biologics Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.1.1. Growing Prevalence Of Chronic Conditions
3.2.1.2. Increased Investment in Research Activities
3.2.2. Market Challenges
3.2.2.1. Growth of Biosimilars
3.2.2.2. Challenge 2
3.2.3. Market Opportunities
3.2.3.1. Strong Pipeline Candidates
3.3. Attractive Investment Proposition, by Geography, 2017
3.4. Competitive Landscape, by Key Players, 2017
Chapter 4. Global Biologics Market, by Product, 2016-2026 (US$ Bn)
4.1. Overview
4.2. Recombinant Therapeutic Proteins
4.2.1. Monoclonal Antibodies
4.2.2. Hormones
4.2.3. Cytokines
4.2.4. Enzymes
4.3. Blood & Blood components
4.4. Cellular & Gene Therapy
4.5. Vaccines
Chapter 5. Global Biologics Market, by Disease, 2016-2026 (US$ Bn)
5.1. Overview
5.2. Oncology
5.2.1. Breast Cancer
5.2.2. Leukemia
5.2.3. Ovarian Cancer
5.2.4. Non-Hodgkin Lymphoma
5.2.5. Prostate Cancer
5.2.6. Colorectal Cancer
5.2.7. Others (bladder cancer, lung cancer, etc.)
5.3. Autoimmune diseases
5.3.1. Systemic Sclerosis
5.3.2. Crohn’s Disease
5.3.3. Rheumatoid arthritis
5.3.4. Systemic Lupus Erythematous
5.3.5. Others (Sjogren’s syndrome, multiple sclerosis, pernicious anemia, etc.)
5.4. Diabetes
5.5. Infectious diseases
5.6. Others (cardiovascular diseases, ophthalmic conditions, dermatological diseases, etc.)
Chapter 6. Global Biologics Market, by Geography, 2016-2026 (US$ Bn)
6.1. Overview
6.2. North America Biologics Market, 2016-2026 (US$ Bn)
6.2.1. North America Biologics Market, by Product, 2016-2026 (US$ Bn)
6.2.2. North America Biologics Market, by Disease, 2016-2026 (US$ Bn)
6.2.3. North America Biologics Market, by Country, 2016-2026 (US$ Bn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Biologics Market, 2016-2026 (US$ Bn)
6.3.1. Europe Biologics Market, by Product, 2016-2026 (US$ Bn)
6.3.2. Europe Biologics Market, by Disease, 2016-2026 (US$ Bn)
6.3.3. Europe Biologics Market, by Country/Region, 2016-2026 (US$ Bn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific Biologics Market, 2016-2026 (US$ Bn)
6.4.1. Asia Pacific Biologics Market, by Product, 2016-2026 (US$ Bn)
6.4.2. Asia Pacific Biologics Market, by Disease, 2016-2026 (US$ Bn)
6.4.3. Asia Pacific Biologics Market, by Country/Region, 2016-2026 (US$ Bn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. Rest of Asia Pacific
6.5. Latin America Biologics Market, 2016-2026 (US$ Bn)
6.5.1. Latin America Biologics Market, by Product, 2016-2026 (US$ Bn)
6.5.2. Latin America Biologics Market, by Disease, 2016-2026 (US$ Bn)
6.5.3. Latin America Biologics Market, by Country, 2016-2026 (US$ Bn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Biologics Market, 2016-2026 (US$ Bn)
6.6.1. Middle East & Africa (MEA) Biologics Market, by Product, 2016-2026 (US$ Bn)
6.6.2. Middle East & Africa (MEA) Biologics Market, by Disease, 2016-2026 (US$ Bn)
6.6.3. Middle East & Africa (MEA) Biologics Market, by Region, 2016-2026 (US$ Bn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA
Chapter 7. Company Profiles
7.1. Merck & Co. Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. AbbVie, Inc.
7.3. AstraZeneca Plc.
7.4. Amgen, Inc.
7.5. Celgene Corporation
7.6. Bristol-Myers Squibb Co.
7.7. Eli Lilly and Company
7.8. Janssen Pharmaceuticals, Inc.
7.9. GlaxoSmithKline Plc.
7.10. Novartis AG
7.11. Pfizer, Inc.
7.12. Novo Nordisk A/S
7.13. Sanofi S.A
7.14. Roche Holding AG
7.15. Takeda Pharmaceutical Co., Ltd
List of Figures
FIG. 1 Market Segmentation: Global Biologics Market
FIG. 2 Biologics Market: Research Methodology
FIG. 3 Global Biologics Market, by Product, 2016-2026 (US$ Bn)
FIG. 4 Global Biologics Market, by Disease, 2016-2026 (US$ Bn)
FIG. 5 Global Biologics Market , by Geography, 2016-2026 (US$ Bn)
FIG. 6 Attractive Investment Proposition, by Geography, 2017
FIG. 7 Competitive Analysis: Global Biologics Market, by Key Players, 2017
FIG. 8 Global Monoclonal Antibodies Market, 2016-2026 (US$ Bn)
FIG. 9 Global Hormones Market, 2016-2026 (US$ Bn)
FIG. 10 Global Cytokines Market, 2016-2026 (US$ Bn)
FIG. 11 Global Enzymes Market, 2016-2026 (US$ Bn)
FIG. 12 Global Blood & Blood Components Market, 2016-2026 (US$ Bn)
FIG. 13 Global Cellular & Gene Therapy Market, 2016-2026 (US$ Bn)
FIG. 14 Global Vaccines Market, 2016-2026 (US$ Bn)
FIG. 15 Global Breast Cancer Market in Biologics, 2016-2026 (US$ Bn)
FIG. 16 Global Leukemia Market in Biologics, 2016-2026 (US$ Bn)
FIG. 17 Global Ovarian Cancer Market in Biologics, 2016-2026 (US$ Bn)
FIG. 18 Global Non-Hodgkin Lymphoma Market in Biologics, 2016-2026 (US$ Bn)
FIG. 19 Global Prostate Cancer Market in Biologics, 2016-2026 (US$ Bn)
FIG. 20 Global Colorectal Cancer Market in Biologics, 2016-2026 (US$ Bn)
FIG. 21 Global Other Cancers Market in Biologics, 2016-2026 (US$ Bn)
FIG. 22 Global Systemic Sclerosis Market in Biologics, 2016-2026 (US$ Bn)
FIG. 23 Global Crohn’s Disease Market in Biologics, 2016-2026 (US$ Bn)
FIG. 24 Global Rheumatoid Arthritis Market in Biologics, 2016-2026 (US$ Bn)
FIG. 25 Global Systemic Lupus Erythematous Market in Biologics, 2016-2026 (US$ Bn)
FIG. 26 Global Other Autoimmune Diseases Market in Biologics, 2016-2026 (US$ Bn)
FIG. 27 U.S. Biologics Market, 2016-2026 (US$ Bn)
FIG. 28 Canada Biologics Market, 2016-2026 (US$ Bn)
FIG. 29 U.K. Biologics Market, 2016-2026 (US$ Bn)
FIG. 30 Germany Biologics Market, 2016-2026 (US$ Bn)
FIG. 31 Rest of Europe Biologics Market, 2016-2026 (US$ Bn)
FIG. 32 Japan Biologics Market, 2016-2026 (US$ Bn)
FIG. 33 China Biologics Market, 2016-2026 (US$ Bn)
FIG. 34 Rest of Asia Pacific Biologics Market, 2016-2026 (US$ Bn)
FIG. 35 Brazil Biologics Market 2016-2026 (US$ Bn)
FIG. 36 Mexico Biologics Market 2016-2026 (US$ Bn)
FIG. 37 Rest of Latin America Biologics Market 2016-2026 (US$ Bn)
FIG. 38 GCC Biologics Market 2016-2026 (US$ Bn)
FIG. 39 Rest of MEA Biologics Market 2016-2026 (US$ Bn)
List of Tables
TABLE 1 Global Biologics Market Portraiture
TABLE 2 Global Biologics Market, by Product, 2016-2026 (US$ Bn)
TABLE 3 Global Recombinant Therapeutic Proteins Market, by Class, 2016-2026 (US$ Bn)
TABLE 4 Global Biologics Market, by Disease, 2016-2026 (US$ Bn)
TABLE 5 Global Oncology Market, by Disease Type, 2016-2026 (US$ Bn)
TABLE 6 Global Autoimmune Diseases Market, by Disease Type, 2016-2026 (US$ Bn)
TABLE 7 Global Biologics Market , by Geography, 2016-2026 (US$ Bn)
TABLE 8 North America Biologics Market, by Product, 2016-2026 (US$ Bn)
TABLE 9 North America Biologics Market, by Disease, 2016-2026 (US$ Bn)
TABLE 10 North America Biologics Market, by Country, 2016-2026 (US$ Bn)
TABLE 11 Europe Biologics Market, by Product, 2016-2026 (US$ Bn)
TABLE 12 Europe Biologics Market, by Disease, 2016-2026 (US$ Bn)
TABLE 13 Europe Biologics Market, by Country/Region, 2016-2026 (US$ Bn)
TABLE 14 Asia Pacific Biologics Market, by Product, 2016-2026 (US$ Bn)
TABLE 15 Asia Pacific Biologics Market, by Disease, 2016-2026 (US$ Bn)
TABLE 16 Asia Pacific Biologics Market, by Country/Region, 2016-2026 (US$ Bn)
TABLE 17 Latin America Biologics Market, by Product, 2016-2026 (US$ Bn)
TABLE 18 Latin America Biologics Market, by Disease, 2016-2026 (US$ Bn)
TABLE 19 Latin America Biologics Market, by Country, 2016-2026 (US$ Bn)
TABLE 20 Middle East And Africa Biologics Market, by Product, 2016-2026 (US$ Bn)
TABLE 21 Middle East And Africa Biologics Market, by Disease, 2016-2026 (US$ Bn)
TABLE 22 Middle East And Africa Biologics Market, by Region, 2016-2026 (US$ Bn)
TABLE 23 Merck & Co. Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 AbbVie, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 AstraZeneca Plc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments) Amgen, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Celgene Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Bristol-Myers Squibb Co. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 Eli Lilly and Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 Janssen Pharmaceuticals, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 30 GlaxoSmithKline Plc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 31 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 32 Pfizer, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 33 Novo Nordisk A/S: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 34 Sanofi S.A: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 35 Roche Holding AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 36 Takeda Pharmaceutical Co., Ltd. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)